News
The day at a glance · 2 min read
Mood · Cautious
+15
Sentiment, −100 to +100
Regeneron BARDA Extension
$270m
Merck/Moderna Recurrence Risk Reduction
42%
Moderna Share Decline
8%-8%
Key driverLate-stage clinical trial readouts from major oncology and immunology programs drove mixed sentiment as investors weighed pipeline progress against valuation concerns
Daily briefHealthcare· Money365.Market AI ·

Pharma Giants Post Phase 3 Wins Amid Biotech M&A Chatter

Regeneron, Merck and Bristol Myers report positive trial data while ImmunityBio draws takeover speculation

Big Pharma & Biotech

Neutral
01REGN
Regeneron Pharmaceuticals (REGN) has agreed to a $270m extension with BARDA within the US Department of Health and Human Services to supply Ebola medicine in the United States. The company also reported nearly four-year Phase 3 C-POST data for Libtayo showing sustained overall survival and disease-free survival benefit in high-risk cutaneous squamous cell carcinoma patients post-surgery. Investigators observed that Libtayo's survival benefit remained in place regardless of minimal residual disease status and despite high placebo crossover.
02MRK▼ -3.21%
Merck & Co (MRK) and Moderna (MRNA) reported detailed Phase 3 data for their individualized mRNA melanoma vaccine plus KEYTRUDA at ESMO 2026, showing a 42% reduction in disease recurrence or death risk. The Phase 3 trial demonstrated significant reduction in disease recurrence and distant metastasis in melanoma patients receiving the combination regimen. The results have been accepted for publication in The New England Journal of Medicine, adding peer-reviewed validation for the program. Despite positive data being called transformational by investigators, Moderna shares fell 8% as investors assessed commercial implications.
03BMY
Bristol Myers Squibb (BMY) reported interim Phase 1 Breakfree-2 data on zola-cel CAR-T therapy in multiple sclerosis showing early efficacy signals including complete B-cell depletion and patients remaining off disease-modifying therapies. The company also reported a fatal event in the trial, providing investors more detail on zola-cel's emerging risk profile. Separately, the company's cancer drug developed with its Chinese partner showed strong results in a late-stage clinical trial, doubling survival time without progression.
04IBRX
ImmunityBio (IBRX) drew attention from market commentators amid a biotech takeover wave, with the company expecting results from a 366-patient Anktiva trial in November and planning a fourth-quarter FDA filing. The stock rose overnight following positive commentary on its potential as a speculative investment in the current M&A environment.

Corporate Governance & Valuation

Neutral

Amgen 5-Year Share Gain

147.6%+147.6%
01AMGN▲ +1.22%
Amgen Inc (AMGN) announced the appointment of David W. Gibbs to its Board of Directors, effective immediately, with Gibbs serving on the Board's Audit Committee and Compensation and Management Development Committee. The company's shares have delivered a 147.6% gain over the past five years, raising investor questions about whether current cash flows and their projected path support today's valuation. Analysts noted that a stream of high-profile clinical wins has kept the story in the spotlight as the market references significant future cash generation expectations.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy